Innova Captab Ltd

Innova Captab Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Innova Captab Ltd

₹ 454 0.48%
10 May 10:02 a.m.
innovacaptab.com BSE: 544067 NSE : INNOVACAP
About

Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]

Key Points

About the company[1] Sharon is engaged in the business of manufacturing intermediates, API, and formulations. It offers contract manufacturing services for pharmaceutical products and made sales worth 192 Crs.

Website BSE NSE
  • Market Cap ₹ 2,601 Cr.
  • Current Price ₹ 454
  • High / Low ₹ 590 / 443
  • Stock P/E 45.3
  • Book Value ₹ 52.1
  • Dividend Yield 0.00 %
  • ROCE 21.6 %
  • ROE 23.9 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 29.0%

Cons

  • Stock is trading at 8.68 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2022 Dec 2022 Jun 2023 Sep 2023 Dec 2023
225 228 219 212 236
196 200 191 185 206
Operating Profit 29 29 28 26 31
OPM % 13% 13% 13% 12% 13%
2 3 1 2 2
Interest 5 5 4 5 4
Depreciation 3 2 3 3 3
Profit before tax 23 24 21 20 26
Tax % 25% 32% 29% 29% 27%
17 16 15 14 19
EPS in Rs 3.56 3.36 3.19 3.01 3.26
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023
373 411 785 859
322 356 687 760
Operating Profit 51 54 99 99
OPM % 14% 13% 13% 11%
1 1 3 9
Interest 5 4 5 18
Depreciation 10 6 7 11
Profit before tax 38 46 89 78
Tax % 26% 26% 25% 26%
28 34 66 58
EPS in Rs 232.42 287.50 551.50 11.99
Dividend Payout % 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 32%
TTM: 9%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 27%
TTM: -13%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 29%
Last Year: 24%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 12 12 12 48 48
Reserves 98 133 199 220 250
54 45 176 235 359
81 178 157 174 200
Total Liabilities 245 368 544 678 857
73 79 161 161 161
CWIP 0 7 0 22 172
Investments 0 0 60 60 60
172 282 322 435 464
Total Assets 245 368 544 678 857

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023
31 42 58 39
-6 -20 -188 -88
-23 -19 125 51
Net Cash Flow 1 3 -5 3

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 85 123 81 98
Inventory Days 84 107 63 53
Days Payable 92 132 84 81
Cash Conversion Cycle 77 99 60 70
Working Capital Days 80 73 74 87
ROCE % 28% 33% 22%

Shareholding Pattern

Numbers in percentages

Dec 2023Mar 2024
50.90% 50.90%
3.57% 1.94%
10.31% 20.78%
35.22% 26.39%
No. of Shareholders 1,39,11739,396

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

No data available.

DRHP

Credit ratings

Concalls